share_log

Connect Biopharma | 6-K: Report of foreign private issuer (related to financial reporting)

Connect Biopharma | 6-K: Report of foreign private issuer (related to financial reporting)

康乃德生物 | 6-K:外国发行人报告(业绩相关)
美股SEC公告 ·  12/23 16:07

Moomoo AI 已提取核心信息

Connect Biopharma appointed CBIZ CPAs P.C. as its new independent registered public accounting firm on December 17, 2024, replacing PricewaterhouseCoopers Zhong Tian LLP (PwC China). The change, approved by the Audit Committee, followed PwC China's dismissal on December 10, 2024. PwC China's reports for 2022 and 2023 contained no adverse opinions or modifications.The company reported no disagreements with PwC China on accounting principles, financial statement disclosure, or auditing procedures during the fiscal years 2022, 2023, and the subsequent interim period. Connect Biopharma confirmed it had not consulted CBIZ on any accounting or auditing matters prior to the appointment.Additionally, on December 11, 2024, Zheng Wei, Ph.D. and Wubin Pan, Ph.D., MBA resigned from the company's Board of Directors as part of a previously announced leadership transition. The company plans to incorporate these changes into its Form 20-F for the year ending December 31, 2024.
Connect Biopharma appointed CBIZ CPAs P.C. as its new independent registered public accounting firm on December 17, 2024, replacing PricewaterhouseCoopers Zhong Tian LLP (PwC China). The change, approved by the Audit Committee, followed PwC China's dismissal on December 10, 2024. PwC China's reports for 2022 and 2023 contained no adverse opinions or modifications.The company reported no disagreements with PwC China on accounting principles, financial statement disclosure, or auditing procedures during the fiscal years 2022, 2023, and the subsequent interim period. Connect Biopharma confirmed it had not consulted CBIZ on any accounting or auditing matters prior to the appointment.Additionally, on December 11, 2024, Zheng Wei, Ph.D. and Wubin Pan, Ph.D., MBA resigned from the company's Board of Directors as part of a previously announced leadership transition. The company plans to incorporate these changes into its Form 20-F for the year ending December 31, 2024.
康乃德生物于2024年12月17日任命CBIZ CPAs P.C.为其新的独立注册公共会计师事务所,取代普华永道中天会计师事务所(PwC中国)。这一变更得到了审计委员会的批准,紧随PwC中国于2024年12月10日被解雇。PwC中国的2022年和2023年的报告没有包含任何不利意见或修改。公司报告称,在2022年、2023年和随后的一段期间,与PwC中国在会计原则、财务报表披露或审计程序方面没有任何分歧。康乃德生物确认在任命之前并未就任何会计或审计事务咨询CBIZ。此外,在2024年12月11日,郑伟博士和潘无彬博士、MBA作为之前宣布的领导过渡的一部分,辞去了公司董事会的职务。公司计划在截至2024年12月31日的20-F表格中纳入这些变更。
康乃德生物于2024年12月17日任命CBIZ CPAs P.C.为其新的独立注册公共会计师事务所,取代普华永道中天会计师事务所(PwC中国)。这一变更得到了审计委员会的批准,紧随PwC中国于2024年12月10日被解雇。PwC中国的2022年和2023年的报告没有包含任何不利意见或修改。公司报告称,在2022年、2023年和随后的一段期间,与PwC中国在会计原则、财务报表披露或审计程序方面没有任何分歧。康乃德生物确认在任命之前并未就任何会计或审计事务咨询CBIZ。此外,在2024年12月11日,郑伟博士和潘无彬博士、MBA作为之前宣布的领导过渡的一部分,辞去了公司董事会的职务。公司计划在截至2024年12月31日的20-F表格中纳入这些变更。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息